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Are all cyclin-dependent kinases 4/6 inhibitors created equal?
Antonio Marra 1,2 and Giuseppe Curigliano 1,2
The harnessing in clinical practice of cyclin-dependent kinases 4/6 inhibitors, namely palbociclib, ribociclib, and abemaciclib, has
substantially changed the therapeutic approach for hormone receptor-positive metastatic breast cancer (BC). Phase II–III clinical
trials evaluating the addition of these agents to standard endocrine therapy reported consistent improvements in response rates
and progression-free survival as well as manageable toxicity proﬁles and excellent impact on patients’ quality of life. Hence, pivotal
trials provided comparable results among different cyclin-dependent kinases 4/6 inhibitors, there is an increasing interest in ﬁnding
substantial differences in order to implement their use in clinical practice. The aim of this paper is to summarize the current
evidences raised from preclinical and clinical studies on cyclin-dependent kinases 4/6 inhibitors in BC, focusing on differences in
terms of pharmacological properties, toxicity proﬁle, and patients’ quality of life.
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INTRODUCTION
Cell cycle dysregulation promotes aberrant cell proliferation and is
one of the widely recognized hallmark of cancer.1 In this context,
the action of cyclin-dependent kinases 4/6 (CDK4/6) is necessary
for the transition from G1-to-S phase, being crucial for normal and
cancer cell proliferation.2 The molecular mechanism underlying
these functions includes the activation by D-type cyclin proteins
leading to phosphorylation of retinoblastoma-associated protein
and E2F protein-mediated transcription of cell cycle genes, such as
cyclins A and E.3 Given that the CDK4/6-RB1 axis is critical to cell
cycle progression, it is to be expected that several tumors disrupt
these ﬁne interactions to promote cancer growth.
Hormone receptor (HR)-positive and human epidermal growth
factor receptor 2 (HER2)-negative breast cancer (BC) presents
different degrees that makes itself susceptible for CDK4/6
inhibition. Cyclin D1 is highly expressed in estrogen receptor
(ER)-positive BC, with or without concomitant ampliﬁcation of the
cyclin D1 gene (CCND1). In addition, ER signaling pathway is able
to activate CCND1 gene promoter.4,5 Cyclin D1 can also stimulate
ER transcriptional activity in a CDK 4-independent manner.6 On
the other hand, cyclin E expression is reported as low in ER-
positive BC7 and RB mutations are rarely found,8 reﬂecting the
dependence of ER-positive BC cells on cyclin D1 to start G1-to-S
phase transition. Furthermore, cyclin D1 and CDK 4 are able to
guide cell proliferation also in an ER-independent manner.9 Given
these data, pharmacological inhibition of CDK 4/6 represents an
appealing and interesting therapeutic strategy to treat HR-positive
BC. Selective CDK 4/6 inhibitors (CDK4/6-Is) have been developed
and tested in HR-positive BC patients, mainly in combination with
endocrine therapy. To date, three CDK4/6-Is have been evaluated
in clinical trials with published results: palbociclib (PD0332991;
Ibrance, Pﬁzer, United States), ribociclib (LEE011; Kisquali, Novartis,
Switzerland), and abemaciclib (LY2835219, Verzenio, Lilly, United
States). On the basis of the results obtained in pivotal trials, these
CDK4/6-Is are United Stated Food and Drug Administration (FDA)
and European Medicines Agency (EMA) approved for the
treatment of HR-positive metastatic BC (mBC) in combination
with aromatase inhibitors or fulvestrant both in ﬁrst and advanced
lines of therapy.
Given that these agents have been developed almost at the
same time and comparable results have been provided, there is an
increasing interest in ﬁnding differences between the three drugs
to facilitate their use in clinical practice. In the current paper, we
will describe the current evidences raised from preclinical and
clinical studies on CDK4/6-Is in mBC, focusing on differences in
terms of pharmacological properties, toxicity proﬁle, and patients’
quality of life.
CDK 4/6 INHIBITORS IN METASTATIC ER-POSITIVE BC CARE
CDK4/6 inhibitors highlighted preclinical and clinical activity in BC,
mainly in HR-positive tumors and in combination with endocrine
therapy (Table 1). Hence, endocrine therapy is an effective and
well-tolerated therapeutic option for patients with HR-positive BC,
almost all patients will invariably develop resistance and
experience locoregional and/or distant relapses.10 A key point to
keep in mind when we consider a trial conducted in the
metastatic setting of BC is represented by the presence or
absence of endocrine resistance to previous treatments. In this
regard, the ESO–ESMO International Consensus for Advanced
Breast Cancer provides accurate deﬁnitions, by distinguishing
between primary and secondary (acquired) endocrine resis-
tances.11 Pivotal trials that tested CDK4/6-Is in mBC have been
conducted both within endocrine-sensitive and endocrine-
resistant setting. Figure 1 schematically summarizes the survival
gains obtained in clinical trials that are described below.
PALBOCICLIB: PALOMA TRIALS
Palbociclib is a reversible, small-molecule CDK4/6-I and was the
ﬁrst-in class to show meaningful clinical activity in ER-positive BC
both in preclinical and clinical studies.12,13 Palbociclib showed a
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highly speciﬁc activity against CDK4 and CDK6, with a half
maximal inhibitory concentration (IC50) of 11 and 15 nanomol/
Litre (nM/L), respectively.14 In addition, it demonstrated anti-
proliferative activity against RB-positive tumor cells in vitro,
inducing an exclusive G1 arrest with a concomitant reduction of
phospho-Ser780/Ser795 on the Rb protein.
In the Phase II open-label randomized PALOMA-1/TRIO-18
trial, palbociclib plus letrozole signiﬁcantly increased
progression-free survival (PFS) as compared with letrozole alone
in treatment-naive, postmenopausal HR+/HER2− mBC patients
(20.2 versus 10.2 months).15 Of note, the cohort 2 of PALOMA-1/
TRIO-18 trial enrolled patients with deﬁned molecular altera-
tions, such as CCND1 ampliﬁcation, loss of p16 or both.
However, no predictive role of these biomarkers on palbociclib
efﬁcacy was observed. In elderly patients (age > 65 years),
median PFS conﬁrmed to be signiﬁcantly augmented in
palbociclib arm compared with letrozole-alone arm (26.2 vs
12.9 months).16 An updated analysis revealed that palbociclib
plus letrozole did not increase median overall survival (OS)
compared with letrozole alone (37.5 versus 34.5 months, HR
0.89, p= 0.28).17 Based on the encouraging results of this trial, a
Phase III randomized study was conducted. The Phase III
randomized clinical trial PALOMA-2 enrolled patients with
treatment-naive, endocrine-sensitive postmenopausal HR
+/HER2− mBC. Palbociclib plus letrozole signiﬁcantly improved
median PFS compared with letrozole plus placebo (24.8 vs
14.5 months).18 PSF beneﬁt was maintained in elderly popula-
tion. To date, OS data are still immature.
Furthermore, palbociclib has been also tested in endrocrine-
resistant HR+/HER2− mBC with the Phase III PALOMA-3 trial that
compared the combination of palbociclib and fulvestrant to
fulvestrant and placebo in pre- and postmenopausal HR+/HER2−
mBC patients whose disease either relapsed during or within 1
year after the completion of adjuvant endocrine therapy or
progressed in prior hormonal treatment for metastatic disease.
Although the combination of palbociclib to fulvestrant showed an
increased median PFS (9.5 vs 4.6 months) as compared with
fulvestrant monotherapy,19,20 the updated results of this trial did
not demonstrate a statistically signiﬁcant OS improvement for the
combination (median OS 34.9 vs 28.0; hazard ratio, 0.81;
P= 0.09).21 Interestingly, the addition of palbociclib to fulvestrant
in patients with sensitivity to previous endocrine therapy, either in
the context of metastatic disease or in the adjuvant setting before
recurrence, highlighted OS and PFS gains of 10 and 7.8 months,
respectively. Conversely, these survival beneﬁts were not achieved
in patients with intrinsic endocrine resistance.21
Unlike PALOMA-1 and PALOMA-2, PALOMA-3 study was the ﬁrst
Phase III trial testing a CDK4/6-I to enroll also premenopausal
patients. Among 108 premenopausal HR+mBC patients, median
PFS was 9.5 in the palbociclib arm (palbociclib plus fulvestran and
goserelin) versus 5.6 months in placebo arm.22 Regarding elderly
population, 129 patients aged > 65 were enrolled. Survival beneﬁt
of older patients was comparable to that of younger population.
Interestingly, Turner et al.23 recently published a biomarker
analysis from mBC patients enrolled in the PALOMA-3 trial. The
authors reported that high cyclin E1 (CCNE1) mRNA expression
was associated with a reduced PFS in patients treated with
palbociclib when compared with those with low expression.
These ﬁndings were also conﬁrmed in a validation cohort of BC
patients from the Preoperative Palbociclib study, suggesting a
potential role for CCNE1 as predictor of resistance to CDK4/6
inhibition.
ABEMACICLIB: MONARCH TRIALS
Abemaciclib is also a highly selective, reversible CDK 4/6 inhibitor.
Among all three, CDK 4/6-Is available in clinical practice,
abemaciclib is the most potent with reported IC50s of 2 nM and
10 nM for CDK4 and CDK6, respectively.24 In addition, abemaciclib
has shown a potential for crossing the blood–brain barrier25 and,
in this context, some trials are evaluating abemaciclib in ER-
positive BC patients with brain metastases. Preclinical and early-
phase trials highlighted the activity of abemaciclib in HR-positive
BC, supplying a rationale for further development.24,26
The Phase II open-label MONARCH-1 trial evaluated abemaciclib
monotherapy in endocrine-resistant, chemotherapy-pretreated,
postmenopausal mBC patients, showing objective response rate,
clinical beneﬁt rate, median PFS, and median OS of 19.7%, 42.4%,
6.0, and 17.7 months, respectively.27 Given that results, abemaci-
clib has been also investigated in combination with endocrine
therapy. In the randomized Phase III MONARCH-2 trial, the
combination of abemaciclib and fulvestrant signiﬁcantly pro-
longed median PFS as compared with fulvestrant plus placebo in
endocrine-resistant, chemotherapy-naive, pre- and postmenopau-
sal mBC patients (16.4 versus 9.3 months).28 To date, no data
regarding OS of treated patients have been published. Subgroup
analyses showed no statistically signiﬁcant differences in PFS
beneﬁt between younger and older patients. Furthermore,
abemaciclib was also tested in endocrine-sensitive, postmeno-
pausal mBC patients. The randomized Phase III MONARCH-3 trial
tested abemaciclib plus anastrazole/letrozole versus anastrazole/
letrozole plus placebo, reporting an improved median PFS in
abemaciclib group compared with placebo group (28.1 versus
14.7 months).29,30 Subgroup analysis showed no differences in
efﬁcacy between younger and older patients. OS data were still
immature at time of primary analysis.
Fig. 1 Progression-free survival (PFS) of CDK4/6 inhibitors in clinical trials. Upper and lower panels are referred to endocrine-sensitive and
endocrine-resistant settings, respectively
A. Marra and G. Curigliano
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RIBOCICLIB: MONALEESA TRIALS
Ribociclib is another highly-selective, reversible small-molecule
inhibitor of CDK4/6. Ribociclib showed remarkable preclinical
efﬁcacy as well as acceptable safety proﬁle and preliminary signs
of clinical activity in variety of solid tumors, including HR-positive
BC.31–33 Therefore, several trials investigated ribociclib in
ER+/HER2- mBC.
In the Phase III MONALEESA-2 trial, endocrine-sensitive,
treatment-naive for metastatic disease, postmenopausal mBC
patients were randomized to ribociclib plus letrozole versus
letrozole plus placebo. Median PFS was signiﬁcantly longer in
ribociclib arm than in placebo arm (25.3 versus 16.0 months).34
Furthermore, ribociclib has also been tested in endocrine-
resistant, postmenopausal mBC patients. The randomized Phase
III MONALEESA-3 trial testing ribociclib plus fulvestrant versus
fulvestrant plus placebo reported an improved median PFS in the
ribociclib arm (20.5 vs 12.8 months).35
At last, ribociclib was also evaluated in the ﬁrst-line setting of
pre- and perimenopausal mBC patients. In the Phase III
MONALEESA-7 trial, ribociclib plus anastrazole/letrozole and
LH–RH analog signiﬁcantly increased median PFS compared with
anastrazole/letrozole and LH–RH analog plus placebo (23.8 vs
13.0 months).36 Recently, the updated analysis of this study
showed that the addition of ribociclib to endocrine therapy
signiﬁcantly prolonged OS as compared with endocrine therapy
alone with an estimated OS at 42 months of 70.2% in the ribociclib
group and 46.0% in the placebo group (hazard ratio for death,
0.71; log-rank P= 0.00973).37 To date, MONALEESA-7 has been the
ﬁrst trial investigating CDK4/6 inhibition in mBC to demonstrate
an OS beneﬁt. In addition, this trial enrolled the larger cohort of
premenopausal patients, conﬁrming the results previously
obtained mainly in the postmenopausal population.
HOW TO SELECT THE CDK 4/6 INHIBITOR IN CLINICAL
PRACTICE?
Pharmacological differences
Despite comparable results in terms of clinical efﬁcacy, the three
CDK4/6-Is present substantial pharmacological differences, as
summarized in Table 2.
Palbociclib, ribociclib, and abemaciclib are orally administered
small molecules, which inhibit CDK4 and CDK6 by binding to the
ATP clefts of these molecules. Palbociclib and ribociclib have
similar potencies in terms of CDK4 and CDK6 inhibition with
reported IC50s of 11 and 15 nM (for palbociclib) and 10 and 39 nM
(for ribociclib), respectively. On the other hand, abemaciclib
studies report high IC50s: 2 nM for CDK4 and 10 nM for CDK6.
Concerning target activity, palbociclib and ribociclib are able to
inhibit only CDK4 and CDK6, whereas abemaciclib has an
additional activity against CDK9.3 CDK9 is an enzyme implicated
in the regulation of a broad spectrum of transcriptional events as
well as in embryogenesis and cell proliferation process.38 This
activity against CDK9 could in part explain the clinical efﬁcacy of
abemaciclib monotherapy showed in MONARCH-1 trial27 and the
speciﬁc gastrointestinal toxicity that is less pronounced with
ribociclib and palbociclib.39 In contrast, ribociclib and palbociclib
have greater lipophilicity and different binding-site side chains
compared with abemaciclib. These features could partially clarify
the reduced number of off-target interactions for palbociclib and
ribociclib.40
Concerning drug administration, palbociclib and ribociclib are
administered for 21 days, followed by 7 days off treatment, at the
standard doses of 125mg once daily and 600 mg once daily,
respectively.41,42 Conversely, abemaciclib dosing is 200mg every
12 hours, given continuously.43
All three drugs are mainly metabolized at liver, mainly through
oxidation by the cytochrome P450 3A4 (CYP3A4). In addition,
palbociclib undergoes hepatic metabolism involving also the
sulfotransferase enzyme SULT2A1. Given that pharmacological
property, the concomitant use of strong CYP3A inhibitors (e.g.,
clarithromycin, itraconazole, ketoconazole, ritonavir, and grape-
fruit juice) should be avoided. In patients who need simulta-
neously administration of a strong CYP3A inhibitor, a dose
reduction of palbociclib to 75mg is recommended. Moreover,
also the administration of strong CYP3A inducers (e.g., rifampin,
phenobarbital, St. John’s Wort) should be avoided in order to
prevent palbociclib plasma levels decreasing. As ribociclib and
abemaciclib are metabolized through oxidation via CYP3A4, the
same recommendations reported for palbociclib remain valid.42,43
Interestingly, a common clinical scenario could be represented by
patients who need anticoagulant treatment. As reported in recent
analysis, patients receiving CDK4/6-I have an augmented risk of
thromboembolic events,44 ranged from 0.6 to 5% in the evaluated
trials. Given the increasing use of direct oral anticoagulants
(DOACs) in cancer patients and considering that these drugs have
a liver metabolism,45,46 the concomitant administration of CDK4/6-
I and DOAC has to be carefully discussed in absence of data about
potential pharmacological interactions. Further data on this
relevant topic are strongly warranted.
In cases of mild hepatic impairment (Child-Pugh A and B), no
dose adjustments are required. However, in patients with severe
hepatic dysfunction (Child-Pugh C) it is recommended to start
with reduced doses for all CDK4/6-Is. At last, pharmacokinetic data
about all three drugs in patients affected by severe renal
impairment (CrCl <30ml/min) are still not available. In this context,
further studies evaluating safety and clinical efﬁcacy of CDK4/6-Is
in this patient subgroup are strongly encouraged. Of interest, an
increase in serum creatinine has been associated with abemaciclib
administration.27 This effect is related to an on-target effect of
abemaciclib, which competitively inhibits the renal tubular
secretion transporters OCT2 and MATE, without affecting glomer-
ular ﬁltration.47
Toxicities
In terms of toxicity proﬁle, the three CDK4/6-Is present few, but
consistent differences. Overall, palbociclib and ribociclib presents
with a predominant bone marrow toxicity. Conversely, abemaci-
clib administration has been correlated with gastrointestinal
symptoms and less-pronounced hematologic toxicity (Table 3
and Figs 2 and 3).
In PALOMA trials, the most commonly reported grade 3–4
adverse events (AEs) were neutropenia (54–66%), leukopenia
(19–25%), anemia (2–6%), and fatigue (2–4%). As for palbociclib,
the hematological AEs are common with ribociclib. Differently, the
MONALEESA trials highlighted other relevant toxicities. Grade 3–4
aspartate aminotransferase and alanine aminotransferase eleva-
tions occurred in 5–10% of patients treated with ribociclib.
Regarding liver abnormalities, liver function tests should be
obtained before initiating treatment with ribociclib and monitored
at the beginning of each subsequent cycle. Furthermore, ribociclib
administration has been associated with QT interval prolongation
in ~1–3% of treated patients.34–36 In this context, the use of
ribociclib in patients with signiﬁcant risk of developing QTc
prolongation, such as those affected by long QT syndrome,
uncontrolled or signiﬁcant cardiac disease, recent myocardial
infarction, congestive heart failure, unstable angina, bradyarrhyth-
mias, and uncontrolled electrolyte abnormalities, should not
receive ribociclib. In addition, the avoidance of QT-prolonging
agents, including ﬂuoroquinolones, ketoconazole, itrokonazole,
some antidepressant (citalopram, escitalopram, mirtazapine,
venlafaxine) and some antipsychotic agents (haloperidol, sulpiride,
pimozide, chlorpromazine),48 as well as an adequate supplemen-
tation for electrolyte alterations are recommended.49 Electrocar-
diogram has to be performed at baseline and repeated at day 14
A. Marra and G. Curigliano
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of the ﬁrst cycle, at the beginning of the second cycle, and then as
clinically indicated; electrolytes have to be dosed at baseline and
monitored during the treatment in all patients.
Despite the high frequency of neutropenia for all CDK4/6-Is (in
particular, palbociclib and ribociclib), febrile neutropenia and
other serious infections have been rarely reported in clinical trials,
ranged from 1 to 2% in palbociclib and ribociclib trials and <1% in
abemaciclib trials (Table 1). Dose reductions for palbociclib and for
persistent neutropenia are common. Reassuringly, dose modiﬁca-
tions for grade 3–4 neutropenia have not a deleterious effect on
PFS.50
At last, abemaciclib had lower rates of neutropenia but greater
degrees of diarrhea compared with the other agents. However,
the majority of patients did not require treatment modiﬁcation for
this kind of toxicity, being well managed with antidiarrhoeic
medications.
Patient-reported outcomes
As shown above, the addition of CDK4/6-I to endocrine therapy
signiﬁcantly contributes to improve response rates and survival
times in ER+/HER2- mBC patients. However, it is critical to
understand the impact of these therapies on QoL of treated
patients. As such, patient-reported outcomes (PROs) has been
demonstrated to be integral components for tabulating sympto-
matic toxicities, enabling symptoms that could be underestimated
by clinicians, and assessing beneﬁt–risk of new treatment
regimens.51 Some trials testing CDK4/6-Is reported PROs together
with results on efﬁcacy and toxicity.
Table 2. Pharmacological characteristics of CDK4/6 inhibitors
Palbociclib (pd-0332991; ibrance,
pﬁzer)
Abemaciclib (ly2835219;
verzenio, lilly)
Ribociclib (lee011; kisquali, novartis)
Chemical structure
Ic50 (nm)
Cdk4-cyclin d1 11 2 10
Cdk6-cyclin d1-2-3 15 10 39
Absorption Increased with high-fat, high-
calorie food
NR NR
Distribution 2583 L 690.3 L 1090 L
Metabolism Liver (cyp3a and sult2a1) Liver (cyp3a4) Liver (cyp3a4)
Excretion Feces (~74%) Feces (~81%) Feces (~69%)
Urine (~18%) Urine (~3%) Urine (~23%)
Bioavailability 46% 45% NR
Time to peak (hours) 6–12 8 1–4
Half-life elimination
(hours)
29 ± 5 18.3 30–55
Protein binding ~85% 93–98% ~70%
Mtd/rp2d 125/125mg/day on a 21-of-28-day
schedule
200mg twice daily 900/600mg/day on a 21-of-28-day schedule
Dlts Neutropenia Fatigue Neutropenia, asymptomatic thrombocytopenia,
mucositis, pulmonary embolism, hyponatremia,
QTcF, prolongation (> 500ms), increased
creatinine
Route of administration Oral Oral Oral
Recommended dose 125mg once daily for 21 days,
followed by 7 days off, repeat every
28 days
150mg twice daily 600mg once daily for 21 days, followed by 7 days
off, repeat every 28 daysDose modiﬁcations
Renal impairment
Crcl > 15ml/min No dosage adjustament No dosage adjustament No dosage adjustament
Crcl ≤ 15ml/min NR NR NR
Esrd NR NR NR
Hepatic impairment*
Mild/moderate No dosage adjustament No dosage adjustament No dosage adjustament
Severe Reduce dose to 75mg Reduce dose to once daily Reduce dose to 400mg
Chemical structures are available online at: https://pubchem.ncbi.nlm.nih.gov. Data about pharmacological characteristics of the three drugs are available
online at: https://www.drugs.com
DLT dose-limiting toxicity, ESRD end-stage renal disease, IC50 half maximal inhibitory concentration, MTD maximum tolerated dose, NR not reported, RP2D
recommended phase II dose
*Mild, moderate, and severe hepatic impairment refers to Child-Pugh classes A, B, and C, respectively
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In the PALOMA-2 trial, the addition of palbociclib to letrozole
maintained health-related QOL, evaluated by means Functional
Assessment of Cancer Therapy (FACT)-Breast Total, FACT-General
Total, and EuroQOL-5 dimensions scores.52 In addition, the
palbociclib group presented an improvement in pain scores. In
both arms, patients without signs of clinical or radiological disease
progression presented with a delayed worsening of FACT-Breast
Total score compared with those with progression. Comparable
results were obtained in the PALOMA-3 trial: overall global QoL
scores, evaluated through the European Organization for Research
and Treatment of Cancer Quality-of-Life C30 (EORTC QLQ-C30)
questionnaire, signiﬁcantly favored the palbociclib plus fulvestrant
group along with a greater improvement from baseline in pain
control.53
As for palbociclib trials, PROs were also reported for ribociclib
studies. In the MONALEESA-2 trial, on-treatment HRQoL scores,
using the EORTC QLQ-C30 questionnaire, were consistently
maintained from baseline and were similar between the two
arms.54 A clinically meaningful reduction in pain score was
observed in the ribociclib arm. Similar results were reported in the
MONALEESA-3 trial whereby the combination of ribociclib and
fulvestrant maintains QoL compared with fulvestrant plus
placebo.55 Moreover, in the MONALEESA-7 trials median time to
deﬁnitive deterioration of QoL, measured by the EORTC QLQ-C30,
was not reached in the ribociclib group compared with
21.2 months in the placebo group (HR 0.70, p= 0.004). In addition,
a clinically meaningful improvement from baseline in EORTC QLQ-
C30 pain score was observed in the ribociclib group.36
Regarding abemaciclib trials, PROs are available only for the
MONARCH-2 study. In this latter, no signiﬁcant differences in
HRQoL, using the EORTC QLQ-C30, BR-23, and Brief Pain Inventory
short form, were observed between the two arms.56 However,
diarrhea, appetite loss, nausea, and vomiting were worse in the
abemaciclib group.
DISCUSSION
The relevant results obtained with CDK4/6-Is in ER-positive mBC
led to the approval of all three agents by the regulatory agencies.
At present, several open issues remain about the proper
application of these drugs in daily medical practice.
As previously showed, the administration of CDK4/6-Is, mainly
in combination with endocrine therapy, produced substantial
beneﬁt in terms of PFS both in endocrine-sensitive (PALOMA-2,
MONARCH-3, MONALEESA-2, and MONALEESA-7 trials) and in the
endocrine-resistant (PALOMA-3, MONARCH-2, and MONALEESA-3
trials) mBC patients. Of note, MONALEESA-7 has been the ﬁrst trial,
which evaluated CDK4/6-Is in mBC, to demonstrate a signiﬁcant
improvement in terms of OS.37 Considering exclusively the trials
testing the addiction of CDK4/6 inhibition in endocrine-resistant
patients, the PALOMA-3 study results highlighted that patients
with previous sensitivity to endocrine therapy presented had an
OS beneﬁt of about 10 months with addiction of palbociclib,
although this improvement was not seen in the overall popula-
tion.21 In this way, further OS data from clinical trials testing CDK4/
6-Is in ER-positive mBC are strongly awaited.
Concerning the safety proﬁle of CDK4/6-Is, some differences
have been reported and have to be considered at the time of drug
choice. Abemaciclib is associated with less-hematologic toxicity
Fig. 2 Common grade 3–4 adverse events reported in pivotal trials
of CDK4/6 inhibitors
Table 3. Common toxicities of CDK 4/6 inhibitors reported in pivotal trials
Neutropenia Febrile
neutropenia
Leukopenia Fatigue Anemia Thrombocytopenia Arthralgia Diarrhea Nausea Vomiting
All grades Paloma-1 74 NR 43 40 35 16 23 21 25 14
Grades 3/4 54 19 4 6 2 1 4 2 0
All grades Paloma-2 79.5 1.8 39 37.4 24.1 15.5 33.3 26.1 35.1 15.5
Grades 3/4 66.5 24.8 1.8 5.4 1.6 0.7 1.4 0.2 0.5
All grades Paloma-3 78.8 1 45.5 38.0 26.1 19.4 13 19.1 29.0 14.5
Grades 3/4 62.0 25.2 2.0 2.6 2.3 0.3 0 0 0.3
All grades Monarch-1 87.7 0.7 90.9 65.2 68.5 41.1 NR 90.2 64.4 34.8
Grades 3/4 26.9 27.7 12.9 0 2.3 NR 19.7 4.5 1.5
All grades Monarch-2 46.0 0.9 28.3 39.9 29.9 15.6 11.6 86.4 45.1 25.9
Grades 3/4 26.5 8.8 2.7 7.2 3.4 0.2 13.4 2.7 0.9
All grades Monarch-3 41.3 0.3 20.8 40.1 28.4 36.2 NR 81.3 38.5 28.4
Grades 3/4 21.1 7.6 1.8 5.8 1.9 NR 9.5 0.9 1.2
All grades Monaleesa-2 74.3 1.5 32.0 36.5 18.6 NR 27.2 35.0 51.5 29.3
Grades 3/4 59.3 21 2.4 1.2 NR 0.9 1.2 2.4 3.6
All grades Monaleesa-3 69.6 1.0 28.4 31.5 17.2 NR 24.0 29.0 45.3 26.7
Grades 3/4 53.4 14.1 1.7 3.1 NR 0.6 0.6 1.4 1.4
All grades Monaleesa-7 76 2 31 23 21 6 30 20 32 19
Grades 3/4 61 14 1 3 1 1 1 1 1
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and more gastrointestinal symptoms, whereas palbociclib pre-
sents a high percentage of grade ¾ neutropenia. In addition,
ribociclib has a potential for QT interval prolongation. In clinical
practice, the different safety proﬁles have to be carefully evaluated
by physicians prior to prescribe one of these drugs. For example,
in patients with cardiac diseases, ribociclib could not be the right
therapeutic choice as well as abemaciclib might not be the right
drug for subjects with preexistent gastrointestinal comorbidities.
Regarding PROs, CDK4/6-I use in ﬁrst-line setting has not been
associated with an improvement in HRQoL,52,54 except in
MONALEESA-7 where median time to deﬁnitive deterioration
was signiﬁcantly reduced in ribociclib arm.36 Interestingly, the
PROs evaluation in PALOMA-2 indicates that disease progression
was associated with degradation of HRQoL, regardless of
palbociclib treatment.52 In the second-line setting, HRQoL
improvement has also been observed.53 Noteworthy, all trials
reported a better pain management in patients treated with the
combination of CDK4/6-I and endocrine therapy.
Another relevant point concerns the implementation of tissue
and/or serum biomarkers, which could adequately select patients
candidate to receive combinatorial therapeutic strategies (CDK4/6-
I + endocrine agent ± other agent) and those who can be can be
treated by endocrine therapy alone. In this regard, the recent
ﬁnding of high CCNE1 expression as resistance mechanism to
palbociclib23 opens the door to further prospective clinical trials
investigating CDK4/6 inhibition in biomarker-deﬁned mBC popu-
lations. Furthermore, the optimal therapeutic sequence as well as
the right treatment after progression on CDK-I remain important
open questions. Ongoing clinical trials, including PARSIFAL
(NCT02491983) and SONIA (NCT03425838), will provide novel
and substantial insights in these clinical contexts.
The substantial results obtained with CDK4/6 inhibition in the
advanced setting prompted clinical research to implement these
agents also in early BC. To date, several clinical trials are testing
the addition of CDK4/6-Is in neoadjuvant and adjuvant settings of
early BC patients, mainly in combination with endocrine therapy.
However, several issues have to be considered about the role of
neoadjuvant treatment of ER-positive BC. The majority of the
neoadjuvant trials in BC are designed with the pathological
complete response (pCR) as primary end-point. Although the pCR
is a recognized surrogate marker of long-term survival in HER2+
and triple-negative BC,57 its value in ER-positive disease is
controversial. Considering the low rates of pCR after endocrine
neoadjuvant therapy58 as well as the possibility to achieve good
survival outcomes with standard (or extended) adjuvant endo-
crine therapy and to tailor the adjuvant treatment on the basis of
several validated prognostic gene signatures,59 other markers of
biological and clinical activity have been implemented and
evaluated in different clinical trials testing neoadjuvant therapies
in ER-positive disease. These include the changes in cell
proliferation rate evaluated by means the Ki67 index, the
preoperative endocrine prognostic index—a composite score of
post-treatment ER, Ki67, tumor size, and axillary nodal status, and
the residual cancer burden index.59 Several trials, such as
NeoPalAna,60 neoMONARCH,61 N007,62 and NeoPAL,63 showed
that the addition of CDK4/6-Is led to cell cycle arrest, deﬁned as a
Ki67 proliferation index <2.7%, 2 weeks after the beginning of
treatment in 68–87% of patients as compared with 14–26% of
patients treated with endocrine therapy alone.64 In another
presurgical, window-of-opportunity study, ribociclib also demon-
strated a remarkable biological activity in ER-positive/HER2-
negative early BC patients, with a signiﬁcant reduction in
proliferation index and CDKs-Rb-E2F pathway proteins.65 However,
as in other trials that tested neoadjuvant endocrine therapy in BC,
these studies did not show substantial improvements in pCR rates
with the addition of CDK4/6-Is. Moreover, the limited information
about the association between Ki67 level changes and long-term
survival outcomes as well as the possible increase in Ki67 value
when CDK4/6 inhibition was stopped in the preoperative period
represent relevant issues to clarify in further studies.
Besides HR-positive disease, CDK4/6-Is are currently investigat-
ing in HER2-overexpressing and triple-negative BCs.47 Further-
more, the recently reported immunomodulatory activity of the
CDK4/6-Is in preclinical tumor models66 paved the way to test
these agents in combination with immune checkpoint inhibitors.
Several trials are currently testing these therapeutic strategies in
solid tumors, including BC. At last, the profound cross-talk
between CDK4/6 and the PI3K-AKT-mTOR pathway provided a
rationale for implementing combinatorial therapeutic strategies.67
In conclusion, palbocilib, ribociclib, and abemaciclib obtained
relevant results and are actually the standard of care for the
treatment of HR-positive mBC patients in ﬁrst, second, and beyond
lines of therapy.11 Because comparable results in terms of clinical
efﬁcacy as well as substantial differences in side effects have been
provided, clinical choice of one of these drugs should rely on
patient preference, administration schedules, and concomitant
diseases. Ongoing clinical trials will deﬁne the role of CDK4/6
inhibition in early BC as well as in other BC subtypes, including
HER2-positive and triple-negative diseases. Given the similar
results in clinical trials testing CDK4/6-Is, observational real-world
studies will be able to provide new insights for the implementa-
tion of these drugs in the clinical practice.
DATA AVAILABILITY
Source data for all ﬁgures and tables are provided in the paper. No new data sets
have been generated or analyzed for this article.
AUTHOR CONTRIBUTIONS
G.C. and A.M. conceived the work, and wrote and drafted the manuscript. All the
authors read and approved the ﬁnal version of the manuscript.
Fig. 3 Effect of toxicity in selecting CDK4/6 inhibitors
A. Marra and G. Curigliano
7
Published in partnership with the Breast Cancer Research Foundation npj Breast Cancer (2019)    27 
ADDITIONAL INFORMATION
Competing interests: G.C. received honoraria for speaker, consultancy, or advisory
role from Roche, Pﬁzer, Novartis, Seattle Genetics, Lilly, Ellipsis. A.M. has no
competing interests to disclose.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional afﬁliations.
REFERENCES
1. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546–1558 (2013).
2. O’Leary, B., Finn, R. S. & Turner, N. C. Treating cancer with selective CDK4/6
inhibitors. Nat. Rev. Clin. Oncol. 13, 417–430 (2016).
3. Chen, P. et al. Spectrum and degree of CDK drug interactions predicts clinical
performance. Mol. Cancer Ther. 15, 2273–2281 (2016).
4. Gillett, C. et al. Ampliﬁcation and overexpression of cyclin D1 in breast cancer
detected by immunohistochemical staining. Cancer Res. 54, 1812–1817 (1994).
5. Kenny, F. S. et al. Overexpression of cyclin D1 messenger RNA predicts for poor
prognosis in estrogen receptor-positive breast cancer. Clin. Cancer Res. 5,
2069–2076 (1999).
6. Neuman, E. et al. Cyclin D1 stimulation of estrogen receptor transcriptional
activity independent of cdk4. Mol. Cell Biol. 17, 5338–5347 (1997).
7. Agarwal, R. et al. Integrative analysis of cyclin protein levels identiﬁes cyclin b1 as
a classiﬁer and predictor of outcomes in breast cancer. Clin. Cancer Res. 15,
3654–3662 (2009).
8. Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast
tumours. Nature 490, 61–70 (2012).
9. Miller, T. W. et al. ERalpha-dependent E2F transcription can mediate resistance to
estrogen deprivation in human breast cancer. Cancer Discov. 1, 338–351 (2011).
10. Hart, C. D. et al. Challenges in the management of advanced, ER-positive, HER2-
negative breast cancer. Nat. Rev. Clin. Oncol. 12, 541–552 (2015).
11. Cardoso, F. et al. 4th ESO-ESMO international consensus guidelines for advanced
breast cancer (ABC 4). Ann. Oncol. 29, 1634–1657 (2018).
12. Finn, R. S. et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially
inhibits proliferation of luminal estrogen receptor-positive human breast cancer
cell lines in vitro. Breast Cancer Res. 11, R77 (2009).
13. Finn, R. et al. Phase I study of PD 0332991, a novel, oral, cyclin-D kinase (CDK) 4/6
inhibitor in combination with letrozole, for ﬁrst-line treatment of metastatic post-
menopausal, estrogen receptor-positive (ER+), human epidermal growth factor
receptor 2 (HER2)-negative breast cancer. Cancer Res. 69, 5069–5069 (2009).
14. Fry, D. W. et al. Speciﬁc inhibition of cyclin-dependent kinase 4/6 by PD 0332991
and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3,
1427–1438 (2004).
15. Finn, R. S. et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combi-
nation with letrozole versus letrozole alone as ﬁrst-line treatment of oestrogen
receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a
randomised phase 2 study. Lancet Oncol. 16, 25–35 (2015).
16. Finn, R. S. et al. Efﬁcacy and safety of palbociclib in combination with letrozole as
ﬁrst-line treatment of ER-positive, HER2-negative, advanced breast cancer:
expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/
TRIO-18. Breast Cancer Res. 18, 67 (2016).
17. Finn, R. S. et al. Overall survival results from the randomized phase II study of
palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline
treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18). J. Clin.
Oncol. 35, 1001–1001 (2017).
18. Finn, R. S. et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J.
Med 375, 1925–1936 (2016).
19. Turner, N. C., Huang Bartlett, C. & Cristofanilli, M. Palbociclib in hormone-receptor-
positive advanced breast cancer. N. Engl. J. Med 373, 1672–1673 (2015).
20. Cristofanilli, M. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo
for treatment of hormone-receptor-positive, HER2-negative metastatic breast
cancer that progressed on previous endocrine therapy (PALOMA-3): ﬁnal analysis
of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet
Oncol. 17, 425–439 (2016).
21. Turner, N. C. et al. Overall survival with palbociclib and fulvestrant in advanced
breast cancer. N. Engl. J. Med. 379, 1926–1936 (2018).
22. Loibl, S. et al. Palbociclib combined with fulvestrant in premenopausal women
with advanced breast cancer and prior progression on endocrine therapy:
PALOMA-3 results. Oncologist 22, 1028–1038 (2017).
23. Turner, N. C. et al. Cyclin E1 expression and palbociclib efﬁcacy in previously
treated hormone receptor-positive metastatic breast cancer. J. Clin. Oncol.
JCO1800925 (2019).
24. Gelbert, L. M. et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219:
in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combi-
nation with gemcitabine. Invest. New Drugs 32, 825–837 (2014).
25. Tolaney, S. M. et al. Abemaciclib for the treatment of brain metastases (BM)
secondary to hormone receptor positive (HR+), HER2 negative breast cancer. J.
Clin. Oncol. 35, 1019–1019 (2017).
26. Patnaik, A. et al. Abstract CT232: clinical activity of LY2835219, a novel cell cycle
inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer.
Cancer Res. 74, CT232 (2014).
27. Dickler, M. N. et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and
CDK6 inhibitor, as a single agent, in patients with refractory HR(+)/HER2(−)
metastatic breast cancer. Clin. Cancer Res. 23, 5218–5224 (2017).
28. Sledge, G. W. Jr. et al. MONARCH 2: abemaciclib in combination with fulvestrant
in women with HR+/HER2- advanced breast cancer who had progressed while
receiving endocrine therapy. J. Clin. Oncol. 35, 2875–2884 (2017).
29. Goetz, M. P. et al. MONARCH 3: abemaciclib as initial therapy for advanced breast
cancer. J. Clin. Oncol. 35, 3638–3646 (2017).
30. Johnston, S. et al. MONARCH 3 ﬁnal PFS: a randomized study of abemaciclib as
initial therapy for advanced breast cancer. NPJ Breast Cancer 5, 5 (2019).
31. O’Brien, N. A. et al. Abstract 4756: In vivo efﬁcacy of combined targeting of CDK4/
6, ER and PI3K signaling in ER+ breast cancer. Cancer Res. 74, 4756–4756 (2014).
32. Infante, J. R. et al. A phase I study of the cyclin-dependent kinase 4/6 inhibitor
ribociclib (LEE011) in patients with advanced Solid tumors and lymphomas. Clin.
Cancer Res. 22, 5696–5705 (2016).
33. Kim, S. et al. Abstract PR02: LEE011: an orally bioavailable, selective small
molecule inhibitor of CDK4/6– reactivating Rb in cancer. Mol. Cancer Ther. 12,
PR02 (2013).
34. Hortobagyi, G. N. et al. Ribociclib as ﬁrst-line therapy for HR-positive, advanced
breast cancer. N. Engl. J. Med 375, 1738–1748 (2016).
35. Slamon, D. J. et al. Phase III randomized study of ribociclib and fulvestrant in
hormone receptor-positive, human epidermal growth factor receptor 2-negative
advanced breast cancer: MONALEESA-3. J. Clin. Oncol. 36, 2465–2472 (2018).
36. Tripathy, D. et al. Ribociclib plus endocrine therapy for premenopausal women
with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a
randomised phase 3 trial. Lancet Oncol. 19, 904–915 (2018).
37. Im, S. A. et al. Overall saurvival with Ribociclib plus endocrine therapy in breast
cancer. N. Engl. J. Med. 381, 307–316 (2019).
38. Garriga, J. & Grana, X. CDK9 inhibition strategy deﬁnes distinct sets of target
genes. BMC Res. Notes 7, 301 (2014).
39. Corona, S. P. & Generali, D. Abemaciclib: a CDK4/6 inhibitor for the treatment of
HR+/HER2- advanced breast cancer. Drug Des. Devel.Ther. 12, 321–330 (2018).
40. Sumi, N. J., Kuenzi, B. M., Knezevic, C. E., Remsing Rix, L. L. & Rix, U. Chemopro-
teomics reveals novel protein and lipid Kinase targets of clinical CDK4/6 inhibi-
tors in lung cancer. ACS Chem. Biol. 10, 2680–2686 (2015).
41. Ibrance (palbociclib). Available at: https://www.accessdata.fda.gov/
drugsatfda_docs/label/2017/207103s004lbl.pdf.
42. Kisqali (ribociclib). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/
label/2017/209092s000lbl.pdf.
43. Abemaciclib. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/
label/2017/208716s000lbl.pdf.
44. Olson, S. R., DeLoughery, T. G. & Shatzel, J. J. Cyclin-dependent kinase inhibitor-
associated thromboembolism. JAMA Oncol. 5, 141–142 (2018).
45. Raskob, G. E. et al. Edoxaban for the treatment of cancer-associated venous
thromboembolism. N. Engl. J. Med. 378, 615–624 (2018).
46. Carrier, M. et al. Apixaban to prevent venous thromboembolism in patients with
cancer. N. Engl. J. Med. 380, 711–719 (2019).
47. Pernas, S., Tolaney, S. M., Winer, E. P. & Goel, S. CDK4/6 inhibition in breast cancer:
current practice and future directions. Ther. Adv. Med. Oncol. 10,
1758835918786451 (2018).
48. Bellet, M. et al. Palbociclib and ribociclib in breast cancer: consensus workshop on
the management of concomitant medication. Ther. Adv. Med. Oncol. 11,
1758835919833867 (2019).
49. Spring, L. M., Zangardi, M. L., Moy, B. & Bardia, A. Clinical management of
potential toxicities and drug interactions related to cyclin-dependent kinase 4/6
inhibitors in breast cancer: practical considerations and recommendations.
Oncologist 22, 1039–1048 (2017).
50. Verma, S. et al. Palbociclib in combination with fulvestrant in women with hor-
mone receptor-positive/HER2-negative advanced metastatic breast cancer:
detailed safety analysis from a multicenter, randomized, placebo-controlled,
phase iii study (PALOMA-3). Oncologist 21, 1165–1175 (2016).
51. Di Maio, M., Basch, E., Bryce, J. & Perrone, F. Patient-reported outcomes in the
evaluation of toxicity of anticancer treatments. Nat. Rev. Clin. Oncol. 13, 319–325
(2016).
A. Marra and G. Curigliano
8
npj Breast Cancer (2019)    27 Published in partnership with the Breast Cancer Research Foundation
52. Rugo, H. S. et al. Impact of palbociclib plus letrozole on patient-reported health-
related quality of life: results from the PALOMA-2 trial. Ann. Oncol. 29, 888–894
(2018).
53. Harbeck, N. et al. Quality of life with palbociclib plus fulvestrant in previously
treated hormone receptor-positive, HER2-negative metastatic breast cancer:
patient-reported outcomes from the PALOMA-3 trial. Ann. Oncol. 27, 1047–1054
(2016).
54. Verma, S. et al. Health-related quality of life of postmenopausal women with
hormone receptor-positive, human epidermal growth factor receptor 2-negative
advanced breast cancer treated with ribociclib + letrozole: results from
MONALEESA-2. Breast Cancer Res. Treat. 170, 535–545 (2018).
55. Fasching, P. A. et al. 290OPatient-reported outcomes (PROs) in advanced breast
cancer (ABC) treated with ribociclib + fulvestrant: Results from MONALEESA-3.
Ann. Oncol. 29 (2018).
56. Kaufman, P. A. et al. Health-related quality of life (HRQoL) in MONARCH 2: Abe-
maciclib plus fulvestrant in women with HR+, HER2- advanced breast cancer
(ABC) who progressed on endocrine therapy. J. Clin. Oncol. 36, 1049–1049 (2018).
57. Cortazar, P. et al. Pathological complete response and long-term clinical beneﬁt
in breast cancer: the CTNeoBC pooled analysis. Lancet 384, 164–172 (2014).
58. Spring, L. M. et al. Neoadjuvant endocrine therapy for estrogen receptor-positive
breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2, 1477–1486
(2016).
59. Guerrero-Zotano, A. L. & Arteaga, C. L. Neoadjuvant trials in ER(+) breast cancer: a
tool for acceleration of drug development and discovery. Cancer Discov. 7,
561–574 (2017).
60. Ma, C. X. et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6
inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive
breast cancer. Clin. Cancer Res. 23, 4055–4065 (2017).
61. Martin, M. et al. Abstract PD5-01: ﬁnal results of NeoMONARCH: A phase 2 neoad-
juvant study of abemaciclib in postmenopausal women with hormone receptor
positive (HR+), HER2 negative breast cancer (BC). Cancer Res. 78, PD5-01 (2018).
62. Chow, L. W. C., Morita, S., Chow, C. Y. C., Ng, W. K. & Toi, M. Neoadjuvant pal-
bociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value.
Endocr. Relat. Cancer 25, 123–130 (2018).
63. Cottu, P. et al. Letrozole and palbociclib versus chemotherapy as neoadjuvant
therapy of high-risk luminal breast cancer. Ann. Oncol. 29, 2334–2340 (2018).
64. Brandao, M. & Ignatiadis, M. CDK4/6 inhibitors as neoadjuvant treatment in breast
cancer-what can we learn? Ann. Oncol. 29, 2274–2278 (2018).
65. Curigliano, G. et al. Ribociclib plus letrozole in early breast cancer: a presurgical,
window-of-opportunity study. Breast 28, 191–198 (2016).
66. Goel, S. et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature 548,
471–475 (2017).
67. Gul, A., Leyland-Jones, B., Dey, N. & De, P. A combination of the PI3K pathway
inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in
hormone receptor-positive breast cancer: a genomic algorithm-based treatment
approach. Am. J. Cancer Res. 8, 2359–2376 (2018).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2019
A. Marra and G. Curigliano
9
Published in partnership with the Breast Cancer Research Foundation npj Breast Cancer (2019)    27 
